Trial Profile

A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary) ; Saxagliptin
Indications Type 2 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

17 Aug 2018 Results published in the Journal of Clinical Endocrinology and Metabolism
15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
09 Dec 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com